Quinolin-2(1H)-one LSF Inhibitors for HCC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatocellular carcinoma (HCC) are inadequate, with limited effectiveness and rapid tumor growth leading to poor prognosis, and there is a need for novel targeted therapies that can inhibit cancer cell proliferation and migration.
Innovation Solution
Development of small-molecule compounds, such as those represented by Formula (I), which inhibit late SV40 factor (LSF), increase tubulin acetylation, and induce cell compaction, thereby inhibiting cancer cell growth and migration, specifically designed to target HCC and other cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and targeted therapies (sorafenib, regorafenib) are used to treat HCC, then some tumor growth inhibition is achieved, but treatment effectiveness is limited and tumors rapidly develop resistance
Solution Approach 1:
The patent extracts and targets a specific molecular mechanism (LSF transcription factor) that drives HCC progression, rather than using broad-spectrum chemotherapy. By isolating and inhibiting this specific oncogenic driver, the treatment achieves more reliable tumor growth inhibition while reducing the likelihood of rapid resistance development compared to conventional therapies.
Solution Approach 2:
The invention changes the therapeutic parameter from non-specific cytotoxicity to specific molecular target inhibition. The small molecule compounds modify the biochemical parameter by blocking LSF-DNA binding and LSF-protein interactions, thereby achieving sustained treatment effectiveness without the rapid resistance seen in conventional therapies.
2Reliability
If surgery is performed on small resectable tumors, then complete removal and cure is achieved, but most patients present with advanced unresectable disease
Solution Approach 1:
The patent enables preliminary systemic treatment with LSF inhibitors that can shrink tumors and convert previously unresectable disease into resectable states. This preliminary pharmacological intervention expands patient eligibility for curative surgery, allowing more patients to eventually achieve complete removal and cure.
3Productivity
If LSF inhibition is achieved to block transcriptional activity, then cancer cell proliferation is inhibited, but understanding of tubulin regulation and acetylation mechanisms is still limited
Solution Approach 1:
The patent uses tubulin acetylation as an intermediary mechanism to achieve LSF inhibition effects. The small molecule compounds act as intermediaries that simultaneously achieve anti-proliferative effects while also modifying tubulin post-translational modifications, thereby providing dual insights into both cancer therapy and microtubule regulation mechanisms.
Data Source
AI summary
The present invention is directed to compositions, methods and kits for treatment of cancer, e.g., hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I) to inhibit tubulin acetylation, to inhibit cell migration, or to modulate cell compaction.